1,633 reports of this reaction
1.8% of all AZITHROMYCIN MONOHYDRATE reports
#12 most reported adverse reaction
ASTHMA is the #12 most commonly reported adverse reaction for AZITHROMYCIN MONOHYDRATE, manufactured by Aurobindo Pharma Limited. There are 1,633 FDA adverse event reports linking AZITHROMYCIN MONOHYDRATE to ASTHMA. This represents approximately 1.8% of all 89,541 adverse event reports for this drug.
Patients taking AZITHROMYCIN MONOHYDRATE who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is a less commonly reported adverse event for AZITHROMYCIN MONOHYDRATE, but still significant enough to appear in the safety profile.
In addition to asthma, the following adverse reactions have been reported for AZITHROMYCIN MONOHYDRATE:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 1,633 FDA reports for AZITHROMYCIN MONOHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 1.8% of all adverse event reports for AZITHROMYCIN MONOHYDRATE, making it a notable side effect.
If you experience asthma while taking AZITHROMYCIN MONOHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.